Biocon Board Approves Unaudited Financial Results and CCD Acquisition

Biocon’s Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2025. Additionally, the board approved the early full redemption of 50,000 Non-Convertible Debentures (NCDs) and the acquisition of Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited from ESOF III Investment Fund and EAAA India Alternatives Limited for ₹300 Crores. The board also approved the issuance of Commercial Papers up to ₹550 Crores.

Financial Results Overview

Biocon’s Board of Directors has officially approved the unaudited financial results for the quarter and half-year which ended on September 30, 2025. These results were reviewed during a board meeting held on November 11, 2025, according to the company’s official announcement. The results have been prepared in accordance with the Indian Accounting Standard (Ind-AS).

Early Redemption of NCDs

The board approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The debentures have a face value of ₹1,00,000 each. In total, the aggregate value amounts to ₹500 Crores. These NCDs were initially issued and allotted on a private placement basis on May 19, 2023. The redemption is conditional on receipt of necessary approvals and consents by January 31, 2026.

Acquisition of CCDs

Biocon will acquire 1,06,86,044 Unlisted, Secured, Compulsorily Convertible Debentures (‘CCDs’) of Biocon Biologics Limited (‘BBL’). The acquisition comes from ESOF III Investment Fund and EAAA India Alternatives Limited. Collectively, this is referred to as “Edelweiss.” The face value of each CCD is ₹10. The aggregate amount is ₹300 Crores and the deal is expected to occur on or before January 30, 2026, subject to approvals.

Commercial Paper Issuance

The Board also approved the issuance of Commercial Papers (CPs) for an amount not exceeding ₹550 Crores. This issuance will occur in one or more tranches through private placement.

Board Meeting Conclusion

The board meeting commenced at 4:30 P.M. and concluded at 5:45 P.M. on November 11, 2025, after which the results and decisions were formally announced.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!